The administration of SGLT2 inhibitors to patients with ACD did not exhibit a significant effect in reducing the risk of MACEs (RR 0.94; 95% CI: 0.86–1.03; p for heterogeneity 0.52; I2 = 0%; p = 0.18) (Figure 5), MI (RR 0.99; 95% CI: 0.85–1.15; p for heterogeneity 0.56; I2 = 0%; p = 0.86) (Figure 5), or stroke (RR 1.06; 95% CI: 0.86–1.30; p for heterogeneity 0.49; I2 = 0%; p = 0.61) (Figure 5). The gene discussed is SLC5A2; the disease is stroke disorder.